Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 1:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 54,961 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Patient Clear all

Conditions: Advanced Solid Tumors, Breast Cancer Recurrent, Ovarian Cancer, High-grade Serous Ovarian Carcinoma, Triple Negative Breast Cancer, sqNSCLC, Squamous Non-small-cell Lung Cancer
Interventions: ATX-295, ATX-295 and bevacizumab (or biosimilar); Drug
Lead sponsor: Accent Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 11
States / cities: Aurora, Colorado • Sarasota, Florida • Detroit, Michigan + 8 more

Conditions: Parkinson's Disease Psychosis
Interventions: Pimavanserin tartrate (ACP-103); Drug
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 26
States / cities: La Habra, California • Laguna Hills, California • Reseda, California + 22 more

Conditions: Ulcerative Colitis
Interventions: infliximab; Biological
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 18
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions: ravuconazole; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Aneurysmal Subarachnoid Hemorrhage
Interventions: Clazosentan, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 11
States / cities: Phoenix, Arizona • Englewood, Colorado • Boston, Massachusetts + 8 more

Conditions: Alzheimer Disease
Interventions: Bapineuzumab 0.5 mg/kg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 51 Years to 90 Years
Enrollment: 494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 66
States / cities: Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 38 more

Conditions: Neoplasms, Non-hematologic - Stage I-III
Interventions: Not listed
Lead sponsor: Lexent Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: San Diego, California

Conditions: Renal Insufficiency
Interventions: Not listed
Lead sponsor: Bracco Diagnostics, Inc; Industry
Eligibility: Not listed
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: GIST and CML
Interventions: imatinib mesylate; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 0 Years to 100 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 9
States / cities: Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 6 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Reldesemtiv, Placebo; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 47
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 41 more

Conditions: Caregiver, Metastatic Gastrointestinal Carcinoma
Interventions: Online Mindfulness Meditation, Questionnaire Administration; Behavioral · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic/Myeloproliferative Neoplasm
Interventions: Azacitidine, Gilteritinib, Venetoclax; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Pain
Interventions: 4PCP Course; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 14 Years to 80 Years
Enrollment: 1,188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: Cleveland, Ohio • Richmond, Virginia • Madison, Wisconsin

Conditions: Diabetes Mellitus, Type 1
Interventions: Pancreatic Islets of Langerhans Cell Transplant; Procedure
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions: triapine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Diabetes Mellitus, Type 2
Interventions: Dulaglutide, Placebo, Insulin Glargine, Metformin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 13
States / cities: Fresno, California • San Mateo, California • Tustin, California + 10 more

Conditions: COVID-19
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 100,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Breast Carcinoma
Interventions: Decision Aid, Discussion, Questionnaire Administration; Other · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: bimatoprost 20 µg generation 2, bimatoprost 15 µg generation 2, bimatoprost 10 µg generation 2, bimatoprost 6 µg generation 2, bimatoprost 15 µg generation 1, bimatoprost 10 µg generation 1, bimatoprost 0.03%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 36
States / cities: Artesia, California • La Jolla, California • Los Angeles, California + 31 more

Conditions: Type 2 Diabetes Mellitus, Obesity
Interventions: Bariatric surgery involving Roux-en-Y gastric bypass, Bariatric surgery involving Laparoscopic adjustable gastric banding, Bariatric surgery involving Laparoscopic sleeve gastrectomy; Procedure
Lead sponsor: Ali Aminian; Other
Eligibility: 20 Years to 65 Years
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 4
States / cities: Boston, Massachusetts • Cleveland, Ohio • Pittsburgh, Pennsylvania + 1 more

Conditions: Metastatic Melanoma, Brain Metastases
Interventions: Ipilimumab, Stereotactic Radiosurgery; Drug · Procedure
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Osteopenia, Osteoporosis
Interventions: Denosumab; Biological
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Buffalo, New York • Cleveland, Ohio

Conditions: Uncontrolled Postoperative Pain
Interventions: 0.375% ROPIVACAINE, placebo; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 40 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Stage IIA Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions: Doxorubicin Hydrochloride, External Beam Radiation Therapy, Ifosfamide, Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study, Placebo, Therapeutic Conventional Surgery; Drug · Radiation · Other + 1 more
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative Colitis

Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation

Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping

A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients

Detection of Tumor DNA in Blood Samples From Patients With Early Stage Cancer and "Healthy Controls"

Evaluation of the Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Without Exposure to Gadolinium Based Contrast Agents (GBCA)

Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Web-based Mindfulness Meditation in Reducing Distress in Participants With Metastatic Gastrointestinal Cancer and Their Caregivers

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Impact of 4PCP on Practitioner and Patient Outcomes

UVA Islet Cell Transplantation in Patients With Type I Diabetes

Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas

A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes

Duke COVID-19 Shared Data and Specimen Repository

Acceptability of 3D Printed Breast Models as Surgical Decision Aids for Breast Cancer Treatment

Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension

Alliance of Randomized Trials of Medicine vs Metabolic Surgery in Type 2 Diabetes

Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery

Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant

Can Post-operative TAP Block Improve Quality of Recovery After C-sections in Patients on Methadone Maintenance?

Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma